Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announce that the Company entered into an exclusive license agreement with The Affiliated Hospital of Southwest Medical University for TBM-001, a radionuclide-drug conjugate drug, on September 14, 2023. Pursuant to the License Agreement, the Affiliated Hospital of SMU granted the Company an exclusive license to research, develop and commercialize TBM-001 globally and is in return entitled to receive certain economic interests such as upfront payment, milestone payments, commission on net sales after launch of the product and revenue sharing of third-party sub-licensing, including upfront payment and milestone payments in the aggregate amount of RMB38.5 million. RDC is an emerging tumor precision diagnostic and therapeutic drug developed based on radionuclide-targeting ligand molecular coupling technology.

RDC uses tumor target-specific molecules as carriers to guide radionuclides to accurately target tumors and achieve brachytherapy, which has unique advantages in early diagnosis of tumors and therapeutic evaluation. TBM-001 is an innovative RDC drug independently developed by the Department of Nuclear Medicine of the Affiliated Hospital of SMU and intended to be used for early diagnosis of bone tumor metastasis and precision targeted therapy. The Department of Nuclear Medicine of the Affiliated Hospital of SMU is an important platform for medical treatment, teaching, scientific research and innovation and transformation in nuclear medicine in Sichuan Province, with deep technical experience in areas such as clinical diagnosis, treatment, research and development of radiopharmaceuticals and clinical transformation.

It possesses a Class IV Radiopharmaceuticals Use Permit and obtained National Drug Clinical Trial Accreditation. In addition to TBM-001, the Company and the Affiliated Hospital of SMU have also initiated the co-development of other RDC drugs targeting unmet clinical needs.